NAMS: FMR reports 11.9M NewAmsterdam shares, 10.0% of class
FMR LLC reports 11.94M NAMS shares, 10.0% of class, as of 09/30/2026 in Schedule 13G/A amendment No. 3.
What this filing says
FMR LLC and Abigail P. Johnson report beneficial ownership of 11,941,763 NewAmsterdam common shares, about 10.0% of the class, as of the stated event date of 09/30/2026. This is an amended Schedule 13G, a passive holder disclosure rather than a sale or purchase announcement. For a shareholder, it shows a large institutional holder at roughly the 10% level.
Key figures
- Shares beneficially owned
- 11,941,763 shares
- Percent of class
- 10.0%
- Sole voting power (FMR LLC)
- 11,931,218 shares
- Sole dispositive power (FMR LLC)
- 11,941,763 shares
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- Schedule 13G:
- A short form filed with the SEC by passive holders of more than 5% of a company's shares, disclosing their stake.
- Beneficial ownership:
- Shares a person controls or can direct, including through voting or disposal power, even if held in another name.
- Sole dispositive power:
- The right to decide alone whether to sell or otherwise dispose of the reported shares.
FAQ
How many NewAmsterdam Pharma shares does FMR LLC report owning?
The filing reports 11,941,763 shares beneficially owned by FMR LLC, equal to 10.0% of the class.
Does Abigail P. Johnson report the same stake as FMR LLC?
Yes, Abigail P. Johnson reports 11,941,763 shares with sole dispositive power and no sole voting power, at 10.0% of the class.
Historical context for NAMS
Across the 4 sessions after earlier NAMS headlines, the stock closed higher 3 times and lower 1 times, with a median move of 4.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NAMS | SPY |
|---|---|---|---|
| Nov 4, 2026 | NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results | +5.2% | +1.7% |
| Jul 21, 2026 | BMO Capital Markets initiated coverage on NewAmsterdam Pharma with a new price targetand 1 other headline that session | +9.0% | +0.8% |
| Mar 18, 2026 | Truist initiated coverage on NewAmsterdam Pharma with a new price target | -3.8% | -1.4% |
| Oct 20, 2025 | H.C. Wainwright resumed coverage on NewAmsterdam Pharma with a new price target | +3.5% | +1.0% |
Keep researching NAMS
- What is Schedule 13G?A short-form SEC disclosure for investors who own more than 5% of a company's voting stock but hold it passively, without intent to influence control.
- Schedule 13D vs 13GSchedule 13D vs 13G explained: who must file when crossing 5% ownership, the 2024 deadlines, how activists differ from passive holders, and what Item 4 reveals.
- NAMS insider tradesEvery buy and sale reported by NewAmsterdam Pharma Company N.V. officers, directors and large holders.
- NAMS earnings historyPast NewAmsterdam Pharma Company N.V. earnings releases, newest first.
- NAMS financial statementsRevenue, profit, cash flow and balance sheet from NewAmsterdam Pharma Company N.V.'s SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Follow NAMS and get a push notification the moment its next story breaks.